Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Radiotherapy | Study Protocol

Treatment of supraglottic squamous cell carcinoma with advanced technologies: observational prospective evaluation of oncological outcomes, functional outcomes, quality of life and cost-effectiveness (SUPRA-QoL)

Authors: S. Hassid, B. Krug, S. Deheneffe, J-F. Daisne, G. Delahaut, G. Lawson, R. Crott, S. Van der Vorst

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Over the past decade, therapeutic options in head and neck supraglottic squamous cell carcinoma have constantly evolved. The classical total laryngectomy has been partially replaced by alternative organ- and function-sparing techniques with the same prognosis but less morbidity, such as Radiotherapy, Transoral Laser Microsurgery (TLM) and Trans-Oral Robotic Surgery (TORS). Up to now, a prospective comparison of these innovant techniques has not been conducted.

Methods/design

We will conduct an original international multicentric prospective nonrandomized clinical trial to compare the efficacy between these treatments (Arm 1: Radiotherapy ± chemotherapy; Arm 2: TLM and Arm 3: TORS) with 4 classes of outcomes: quality of life (QoL), oncological outcomes, functional outcomes and economic resources. The population will include cT1-T2 /cN0-N1/M0 supraglottic squamous cell carcinoma. The primary outcome is a Clinical Dysphagia QoL evaluation assessed by the MD Anderson Dysphagia questionnaire. Secondary outcomes include others QoL evaluation, oncological and functional measures and cost parameters. The sample size needs to reach 36 patients per arm (total 108).

Discussion

In the current literature, no prospective head-to-head trials are available to compare objectively these different treatments. With the increase of highly efficient treatments and the increase of oncological survival, it is imperative also to develop management strategies that optimize QoL and functional results. We will conduct this innovate prospective trial in order to obtain objective data in these two main issues.

Trial registration

NCT05611515 posted on 10/11/2022 (clinicaltrial.fgov).
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Martínez T, Escamilla Y, Gutiérrez M, Bodoque M, Scola B, Vega MF. [Conservation surgery for supraglottic carcinoma. Oncological and functional results]. Acta Otorrinolaringol Esp. 1996;47(2):125–8.PubMed
3.
Laccourreye H, Ménard M, Fabre A, Brasnu D, Janot F. [Partial supracricoid laryngectomy. Technics, indications and results]. Ann Otolaryngol Chir Cervicofac. 1987;104(3):163–73.PubMed
4.
Bussu F, Galli J, Valenza V, D’Alatri L, Pizzuto DA, Almadori G, et al. Evaluation of swallowing function after supracricoid laryngectomy as a primary or salvage procedure. Dysphagia. 2015;30(6):686–94.PubMedCrossRef
5.
Bussu F, Paludetti G, Almadori G, De Virgilio A, Galli J, Miccichè F, et al. Comparison of total laryngectomy with surgical (cricohyoidopexy) and nonsurgical organ-preservation modalities in advanced laryngeal squamous cell carcinomas: A multicenter retrospective analysis. Head Neck. 2013;35(4):554–61.PubMedCrossRef
6.
Orús C, León X, Vega M, Quer M. Initial treatment of the early stages (I, II) of supraglottic squamous cell carcinoma: partial laryngectomy versus radiotherapy. Eur Arch Otorhinolaryngol. 2000;257(9):512–6.PubMedCrossRef
7.
Chun JY, Kim YH, Choi EC, Byeon HK, Jung J, Kim SH. The oncologic safety and functional preservation of supraglottic partial laryngectomy. Am J Otolaryngol. 2010;31(4):246–51.PubMedCrossRef
8.
Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8.PubMedCrossRef
9.
Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12(2):127–36.PubMedPubMedCentralCrossRef
10.
Sanguineti G, Endres EJ, Gunn BG, Parker B. Is there a “mucosa-sparing” benefit of IMRT for head-and-neck cancer? Int J Radiat Oncol Biol Phys. 2006;66(3):931–8.PubMedCrossRef
11.
Rao AR, Jones DA, Mendenhall CM, Rizvi SN, Kirwan J, Morris CG, et al. Radiotherapy Alone or With Chemotherapy in the Management of Carcinoma of the Supraglottic Larynx: A 25-Year Community Hospital Experience. Am J Clin Oncol. 2018;41(9):894–7.PubMedCrossRef
12.
Mendenhall WM, Parsons JT, Mancuso AA, Stringer SP, Cassisi NJ. Radiotherapy for squamous cell carcinoma of the supraglottic larynx: an alternative to surgery. Head Neck. 1996;18(1):24–35.PubMedCrossRef
13.
Bussu F, Miccichè F, Rigante M, Dinapoli N, Parrilla C, Bonomo P, et al. Oncologic outcomes in advanced laryngeal squamous cell carcinomas treated with different modalities in a single institution: a retrospective analysis of 65 cases. Head Neck. 2012;34(4):573–9.PubMedCrossRef
14.
van der Woerd B, Patel KB, Nichols AC, Fung K, Yoo J, MacNeil SD. Functional outcomes in early (T1/T2) supraglottic cancer: a systematic review. J Otolaryngol Head Neck Surg. 2018;47(1):76.PubMedPubMedCentralCrossRef
15.
Eisbruch A, Schwartz M, Rasch C, Vineberg K, Damen E, Van As CJ, et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60(5):1425–39.PubMedCrossRef
16.
Petkar I, Rooney K, Roe JW, Patterson JM, Bernstein D, Tyler JM, et al. DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer. BMC Cancer. 2016;16(1):770.PubMedPubMedCentralCrossRef
17.
Grepl J, Sirak I, Vosmik M, Tichy A. The changes in pharyngeal constrictor muscles related to head and neck radiotherapy: a systematic review. Technol Cancer Res Treat. 2020;19:1533033820945805.PubMedPubMedCentralCrossRef
18.
19.
Bussu F, Almadori G, De Corso E, Rizzo D, Rigante M, Parrilla C, et al. Endoscopic horizontal partial laryngectomy by CO(2) laser in the management of supraglottic squamous cell carcinoma. Head Neck. 2009;31(9):1196–206.PubMedCrossRef
20.
Canis M, Martin A, Ihler F, Wolff HA, Kron M, Matthias C, et al. Results of transoral laser microsurgery for supraglottic carcinoma in 277 patients. Eur Arch Otorhinolaryngol. 2013;270(8):2315–26.PubMedPubMedCentralCrossRef
21.
Weinstein GS, Quon H, Newman HJ, Chalian JA, Malloy K, Lin A, et al. Transoral robotic surgery alone for oropharyngeal cancer: an analysis of local control. Arch Otolaryngol Head Neck Surg. 2012;138(7):628–34.PubMedCrossRef
22.
von Scotti F, Kapsreiter M, Scherl C, Iro H, Bohr C. A 9-year analysis of transoral laser microsurgery (TLM) of head and neck cancer on their potential suitability for transoral robotic surgery (TORS) for estimation of future TORS-specific caseload. Eur Rev Med Pharmacol Sci. 2018;22(10):2949–53.
23.
Moore EJ, Olsen SM, Laborde RR, García JJ, Walsh FJ, Price DL, et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc. 2012;87(3):219–25.PubMedPubMedCentralCrossRef
24.
Weinstein GS, O’Malley BW Jr, Magnuson JS, Carroll WR, Olsen KD, Daio L, et al. Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope. 2012;122(8):1701–7.PubMedCrossRef
25.
Hamilton D, Paleri V. Role of transoral robotic surgery in current head & neck practice. Surgeon. 2017;15(3):147–54.PubMedCrossRef
26.
Weinstein GS, O’Malley BW Jr, Cohen MA, Quon H. Transoral robotic surgery for advanced oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2010;136(11):1079–85.PubMedCrossRef
27.
Doazan M, Hans S, Moriniere S, Lallemant B, Vergez S, Aubry K, et al. Oncologic outcomes with transoral robotic surgery for supraglottic squamous cell carcinoma: Results of the French Robotic Surgery Group of GETTEC. Head Neck. 2018;40(9):2050–9.PubMedCrossRef
28.
Mendelsohn AH, Remacle M, Van Der Vorst S, Bachy V, Lawson G. Outcomes following transoral robotic surgery: supraglottic laryngectomy. Laryngoscope. 2013;123(1):208–14.PubMedCrossRef
29.
Lechien JR, Fakhry N, Saussez S, Chiesa-Estomba CM, Chekkoury-Idrissi Y, Cammaroto G, et al. Surgical, clinical and functional outcomes of transoral robotic surgery for supraglottic laryngeal cancers: a systematic review. Oral Oncol. 2020;109: 104848.PubMedCrossRef
30.
Dabas S, Gupta K, Ranjan R, Sharma AK, Shukla H. Oncological outcome following TORS in HPV negative supraglottic carcinoma. Indian J Cancer. 2019;56(1):9–14.PubMedCrossRef
31.
NCCN.org. NCCN guidelines: Head and Neck Cancer.
32.
Machiels JP, Rene Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75.PubMedCrossRef
33.
Patel KB, Nichols AC, Fung K, Yoo J, MacNeil SD. Treatment of early stage supraglottic squamous cell carcinoma: meta-analysis comparing primary surgery versus primary radiotherapy. J Otolaryngol Head Neck Surg. 2018;47(1):19.PubMedPubMedCentralCrossRef
34.
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019;20(10):1349–59.PubMedCrossRef
35.
Stelmes JJ, Gregoire V, Poorten VV, Golusiñski W, Szewczyk M, Jones T, et al. Organ preservation and late functional outcome in oropharyngeal carcinoma: rationale of EORTC 1420, the “Best of” Trial. Front Oncol. 2019;9:999.PubMedPubMedCentralCrossRef
36.
Huang SH, O'Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18(7):40.
37.
Young J, Badgery-Parker T, Dobbins T, Jorgensen M, Gibbs P, Faragher I, et al. Comparison of ECOG/WHO performance status and ASA score as a measure of functional status. J Pain Symptom Manage. 2015;49(2):258–64.PubMedCrossRef
38.
Hutcheson KA, Barrow MP, Lisec A, Barringer DA, Gries K, Lewin JS. What is a clinically relevant difference in MDADI scores between groups of head and neck cancer patients? Laryngoscope. 2016;126(5):1108–13.PubMedCrossRef
39.
Chen AY, Frankowski R, Bishop-Leone J, Hebert T, Leyk S, Lewin J, et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: the M. D. Anderson dysphagia inventory. Arch Otolaryngol Head Neck Surg. 2001;127(7):870–6.
40.
Singer S, Araújo C, Arraras JI, Baumann I, Boehm A, BrokstadHerlofson B, et al. Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module. Phase III Head Neck. 2015;37(9):1358–67.PubMedCrossRef
41.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.PubMedCrossRef
42.
Fayers PM AN, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring Manual (3rd edition) European Organization for Research and Treatment of Cancer. 2001:83.
43.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.
44.
Goepfert RP, Lewin JS, Barrow MP, Warneke CL, Fuller CD, Lai SY, et al. Grading dysphagia as a toxicity of head and neck cancer: Differences in severity classification based on MBS DIGEST and Clinical CTCAE Grades. Dysphagia. 2018;33(2):185–91.PubMedCrossRef
45.
Rosenbek JC, Robbins JA, Roecker EB, Coyle JL, Wood JL. A penetration-aspiration scale. Dysphagia. 1996;11(2):93–8.PubMedCrossRef
46.
Brusselaers N, Lagergren J. The charlson comorbidity index in registry-based research. Methods Inf Med. 2017;56(5):401–6.PubMedCrossRef
47.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.PubMedPubMedCentralCrossRef
48.
van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15.PubMedCrossRef
49.
Landberg T, Chavaudra J, Dobbs J, Hanks G, Johansson K-A, Möller T, et al. 3. Recommendations for Reporting. Reports of the International Commission on Radiation Units and Measurements. 1993;os-26(1):27–38.
50.
Gregoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014;110(1):172–81.
51.
Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO. TROG consensus guidelines Radiother Oncol. 2018;126(1):3–24.PubMedCrossRef
52.
Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, et al. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiother Oncol. 2019;134:1–9.PubMedCrossRef
53.
Remacle M, Hantzakos A, Eckel H, Evrard AS, Bradley PJ, Chevalier D, et al. Endoscopic supraglottic laryngectomy: a proposal for a classification by the working committee on nomenclature. European Laryngological Society Eur Arch Otorhinolaryngol. 2009;266(7):993–8.PubMedCrossRef
54.
Warner L, O’Hara JT, Lin DJ, Oozeer N, Fox H, Meikle D, et al. Transoral robotic surgery and neck dissection alone for head and neck squamous cell carcinoma: Influence of resection margins on oncological outcomes. Oral Oncol. 2022;130: 105909.PubMedCrossRef
55.
Gorphe P, Simon C. A systematic review and meta-analysis of margins in transoral surgery for oropharyngeal carcinoma. Oral Oncol. 2019;98:69–77.PubMedCrossRef
56.
Cağli S, Yüce I, Yiğitbaşi OG, Güney E. Is routine bilateral neck dissection absolutely necessary in the management of N0 neck in patients with supraglottic carcinoma? Eur Arch Otorhinolaryngol. 2007;264(12):1453–7.PubMedCrossRef
57.
Rodrigo JP, Cabanillas R, Franco V, Suárez C. Efficacy of routine bilateral neck dissection in the management of the N0 neck in T1–T2 unilateral supraglottic cancer. Head Neck. 2006;28(6):534–9.PubMedCrossRef
58.
Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1462–75.PubMedCrossRef
59.
Nakayama M, Holsinger FC, Chevalier D, Orosco RK. The dawn of robotic surgery in otolaryngology-head and neck surgery. Jpn J Clin Oncol. 2019;49(5):404–11.PubMedCrossRef
60.
Hans S, Chekkoury-Idrissi Y, Circiu MP, Distinguin L, Crevier-Buchman L, Lechien JR. Surgical, Oncological, and Functional Outcomes of Transoral Robotic Supraglottic Laryngectomy. Laryngoscope. 2021;131(5):1060–5.PubMedCrossRef
61.
Turner MT, Stokes WA, Stokes CM, Hassid S, Holsinger FC, Lawson G. Airway and bleeding complications of transoral robotic supraglottic laryngectomy (TORS-SGL): A systematic review and meta-analysis. Oral Oncol. 2021;118: 105301.PubMedCrossRef
62.
Gregoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol. 2006;79(1):15–20.PubMedCrossRef
63.
Ringash J, O’Sullivan B, Bezjak A, Redelmeier DA. Interpreting clinically significant changes in patient-reported outcomes. Cancer. 2007;110(1):196–202.PubMedCrossRef
64.
Marta GN, Weltman E, Ferrigno R. Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis. Rev Assoc Med Bras (1992). 2018;64(4):318–23.
65.
Rodin D, Caulley L, Burger E, Kim J, Johnson-Obaseki S, Palma D, et al. Cost-Effectiveness analysis of radiation therapy versus transoral robotic surgery for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2017;97(4):709–17.PubMedCrossRef
66.
Turchetti G, Palla I, Pierotti F, Cuschieri A. Economic evaluation of da Vinci-assisted robotic surgery: a systematic review. Surg Endosc. 2012;26(3):598–606.PubMedCrossRef
67.
68.
Garrido MM, Lum J, Pizer SD. Vector-based kernel weighting: A simple estimator for improving precision and bias of average treatment effects in multiple treatment settings. Stat Med. 2021;40(5):1204–23.PubMedCrossRef
69.
A. B, M. S. An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics. 1998;13(4):397–409.
70.
Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness analysis in R Using a multi-state modeling survival analysis framework: a tutorial. Med Decis Making. 2017;37(4):340–52.PubMedCrossRef
71.
Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–6. Value Health. 2012;15(6):835–42.PubMedCrossRef
Metadata
Title
Treatment of supraglottic squamous cell carcinoma with advanced technologies: observational prospective evaluation of oncological outcomes, functional outcomes, quality of life and cost-effectiveness (SUPRA-QoL)
Authors
S. Hassid
B. Krug
S. Deheneffe
J-F. Daisne
G. Delahaut
G. Lawson
R. Crott
S. Van der Vorst
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10953-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Effect of cumulative radiation exposure from Coronary catheterization on lung cancer mortality

Study Protocol

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

Review

Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges

Research

Metabolic syndrome and the risk of severe cancer events: a longitudinal study in Japanese workers

Research

Immediate histologic correlation in patients with different HPV genotypes and ages: a single center analysis in China

Research

Anatomic versus non-anatomic resection for early-stage intrahepatic cholangiocarcinoma: a propensity score matching and stabilized inverse probability of treatment weighting analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits